ESMO Breast 2020 | Characterizing the immune microenvironment before and following anti-HER2 neoadjuvant therapy

Gaia Griguolo, MD, of the Istituto Oncologico Veneto, Padua, Italy, characterizes the immune microenvironment of early HER2+ breast cancer before and after treatment with lapatinib and trastuzumab without chemotherapy in the context of the PAMELA trial (NCT01973660), and its relationship with intrinsic subtyping and pathologic complete response (pCR). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).